{"pmid":32317408,"title":"Perspectives for repurposing drugs for the coronavirus disease 2019.","text":["Perspectives for repurposing drugs for the coronavirus disease 2019.","The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular.","Indian J Med Res","Cherian, Sarah S","Agrawa, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram","32317408"],"abstract":["The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular."],"journal":"Indian J Med Res","authors":["Cherian, Sarah S","Agrawa, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317408","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijmr.IJMR_585_20","keywords":["coronavirus - covid-19 - drugs - host-based - repurposing - severe acute respiratory syndrome coronavirus 2 - virus-based"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087696740352,"score":8.518259,"similar":[{"pmid":32194980,"pmcid":"PMC7073332","title":"Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.","text":["Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.","Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the \"Complementary Exposure\" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.","Cell Discov","Zhou, Yadi","Hou, Yuan","Shen, Jiayu","Huang, Yin","Martin, William","Cheng, Feixiong","32194980"],"abstract":["Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the \"Complementary Exposure\" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2."],"journal":"Cell Discov","authors":["Zhou, Yadi","Hou, Yuan","Shen, Jiayu","Huang, Yin","Martin, William","Cheng, Feixiong"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194980","week":"202012|Mar 16 - Mar 22","doi":"10.1038/s41421-020-0153-3","keywords":["bioinformatics","comparative genomics","proteomic analysis"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Toremifene","Emodin","Dactinomycin","Mercaptopurine","Melatonin","Sirolimus"],"_version_":1664640930732310529,"score":385.86572},{"pmid":32290293,"title":"A Review of SARS-CoV-2 and the Ongoing Clinical Trials.","text":["A Review of SARS-CoV-2 and the Ongoing Clinical Trials.","The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.","Int J Mol Sci","Tu, Yung-Fang","Chien, Chian-Shiu","Yarmishyn, Aliaksandr A","Lin, Yi-Ying","Luo, Yung-Hung","Lin, Yi-Tsung","Lai, Wei-Yi","Yang, De-Ming","Chou, Shih-Jie","Yang, Yi-Ping","Wang, Mong-Lien","Chiou, Shih-Hwa","32290293"],"abstract":["The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis."],"journal":"Int J Mol Sci","authors":["Tu, Yung-Fang","Chien, Chian-Shiu","Yarmishyn, Aliaksandr A","Lin, Yi-Ying","Luo, Yung-Hung","Lin, Yi-Tsung","Lai, Wei-Yi","Yang, De-Ming","Chou, Shih-Jie","Yang, Yi-Ping","Wang, Mong-Lien","Chiou, Shih-Hwa"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290293","week":"202016|Apr 13 - Apr 19","doi":"10.3390/ijms21072657","keywords":["ace2","covid-19","sars-cov-2","clinical trials","immunotherapy","pneumonia","replicase","vaccine"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["favipiravir","Hydroxychloroquine"],"_version_":1664636192536133632,"score":326.86044},{"pmid":32324951,"title":"Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics.","text":["Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics.","The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell surface receptor, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA dependent RNA polymerase for RNA replication. There has been much ground work for drug discovery and development against these targets. Also, high throughput screening efforts led to identification of diverse lead structures, including product-derived molecules. The present review highlights past and present drug discovery and medicinal chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review will stimulate further research and will be a useful guide to the development of effective therapy against COVID-19 and other pathogenic coronaviruses.","ChemMedChem","Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D","32324951"],"abstract":["The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell surface receptor, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA dependent RNA polymerase for RNA replication. There has been much ground work for drug discovery and development against these targets. Also, high throughput screening efforts led to identification of diverse lead structures, including product-derived molecules. The present review highlights past and present drug discovery and medicinal chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review will stimulate further research and will be a useful guide to the development of effective therapy against COVID-19 and other pathogenic coronaviruses."],"journal":"ChemMedChem","authors":["Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324951","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cmdc.202000223","keywords":["covid-19","coronavirus","drug discovery","sars-cov","protease inhibitors"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932679847937,"score":300.33926},{"pmid":32239142,"title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","text":["Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19.","Bioinformatics","Liu, Sen","Zheng, Qiang","Wang, Zhiying","32239142"],"abstract":["MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19."],"journal":"Bioinformatics","authors":["Liu, Sen","Zheng, Qiang","Wang, Zhiying"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239142","week":"202014|Mar 30 - Apr 05","doi":"10.1093/bioinformatics/btaa224","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638354127323136,"score":267.61584},{"pmid":32320852,"title":"Deja vu: stimulating open drug discovery for SARS-CoV-2.","text":["Deja vu: stimulating open drug discovery for SARS-CoV-2.","In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.","Drug Discov Today","Ekins, Sean","Mottin, Melina","Ramos, Paulo R P S","Sousa, Bruna K P","Neves, Bruno Junior","Foil, Daniel H","Zorn, Kimberley M","Braga, Rodolpho C","Coffee, Megan","Southan, Christopher","Puhl, Ana C","Andrade, Carolina Horta","32320852"],"abstract":["In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery."],"journal":"Drug Discov Today","authors":["Ekins, Sean","Mottin, Melina","Ramos, Paulo R P S","Sousa, Bruna K P","Neves, Bruno Junior","Foil, Daniel H","Zorn, Kimberley M","Braga, Rodolpho C","Coffee, Megan","Southan, Christopher","Puhl, Ana C","Andrade, Carolina Horta"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320852","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.drudis.2020.03.019","keywords":["covid-19","coronavirus","sars-cov-2","docking","drug discovery","machine learning","open science."],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Zika","Brazil","vitro assays"],"countries":["Brazil"],"countries_codes":["BRA|Brazil"],"_version_":1664815087650603008,"score":264.60062}]}